2023
Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults
Hanseeuw B, Jacobs H, Schultz A, Buckley R, Farrell M, Guehl N, Becker J, Properzi M, Sanchez J, Quiroz Y, Vannini P, Sepulcre J, Yang H, Chhatwal J, Gatchel J, Marshall G, Amariglio R, Papp K, Rentz D, Normandin M, Price J, Healy B, El Fakhri G, Sperling R, Johnson K. Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults. Neurology 2023, 101: e2533-e2544. PMID: 37968130, PMCID: PMC10791053, DOI: 10.1212/wnl.0000000000207962.Peer-Reviewed Original ResearchConceptsAssociated with cognitive declineOlder adultsNon-AD pathologyCognitive declineHippocampal volumeCognitive dataPreclinical Alzheimer Cognitive CompositeInferior temporal tauProspective cohort studyClinically normal older adultsHarvard Aging Brain StudyPittsburgh compound B PET scansOvert cognitive impairmentAnalyzed dataNormal older adultsAging Brain StudyClinically normal adultsLongitudinal associationsAlzheimer's diseaseCohort studyMemory impairmentCognitive compositeCognitive impairmentHippocampal atrophyCognition
2022
Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals
Hong Y, Kim C, Lee J, Sepulcre J. Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals. Scientific Reports 2022, 12: 14307. PMID: 35995824, PMCID: PMC9395408, DOI: 10.1038/s41598-022-18325-2.Peer-Reviewed Original ResearchConceptsApolipoprotein epsilon 4Apolipoprotein epsilon 4 alleleAlzheimer's Disease Neuroimaging InitiativeApolipoprotein epsilon 4 carriersTau burdenAmyloid depositsAPOE4 non-carriersAssociated with amyloid depositionPresence of ApoE4 alleleCross-sectional studyRegional tau burdenAssess correlationsCognitively normal participantsIncreased amyloid burdenNormal cognitive functionCognitively normal older individualsStandardized uptake value ratioEpsilon 4AD-related biomarkersAPOE4 alleleTau depositionCortical thicknessAmyloidCarrier statusAlleles
2017
In vivo staging of regional amyloid deposition
Grothe M, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel S, Initiative F, Initiative A, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Liu E, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Beckett L, Harvey D, Gamst A, Donohue M, Kornak J, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Ances B, Carroll M, Leon S, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah R, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Coleman R, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Swerdlow R, Apostolova L, Lu P, Bartzokis G, Silverman D, Parfitt F, Johnson H, Farlow M, Hake A, Matthews B, Herring S, van Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Bwayo S, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Longmire C, Spicer K, Finger E, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Ponto L, Shim H, Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Raj B. In vivo staging of regional amyloid deposition. Neurology 2017, 89: 2031-2038. PMID: 29046362, PMCID: PMC5711511, DOI: 10.1212/wnl.0000000000004643.Peer-Reviewed Original ResearchConceptsAmyloid depositionAmyloid pathologyVivo stagingCognitive impairmentPrimary sensory-motor areasAmyloid stagesRegional amyloid depositionCSF Aβ42 levelsAlzheimer's disease dementiaSensory-motor areasAlzheimer's Disease Neuroimaging Initiative (ADNI) cohortNormal older individualsMedial temporal lobeMild cognitive impairmentAβ42 levelsDisease dementiaNeuropathologic observationsInitiative cohortAmyloid positivityTemporal lobeFull cohortCN individualsAssociative neocortexBrain regionsOlder individuals
2015
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson K, Schultz A, Betensky R, Becker J, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, Gomez-Isla T, Hyman B, Vasdev N, Sperling R. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Annals Of Neurology 2015, 79: 110-119. PMID: 26505746, PMCID: PMC4738026, DOI: 10.1002/ana.24546.Peer-Reviewed Original ResearchConceptsPositron emission tomographyCognitive impairmentMild cognitive impairmentClinical impairmentAssociated with clinical impairmentInferior temporal gyrusBrain tau depositionAssociation of cognitive impairmentMild AD dementiaAD dementiaAlzheimer's diseasePositron emission tomographic imagingTau positron emission tomographyTemporal gyrusMonitoring of disease progressionEmission tomographic imagingDisease-modifying therapiesSymptomatic patientsClinically normal individualsPittsburgh compound BControl subjectsDisease progressionClinically normal controlsNormal controlsImpairment